Oramed Pharmaceuticals Inc. (NASDAQ:ORMP – Get Free Report)’s stock price crossed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $2.48 and traded as low as $2.25. Oramed Pharmaceuticals shares last traded at $2.34, with a volume of 44,022 shares.
Oramed Pharmaceuticals Price Performance
The stock has a market capitalization of $94.82 million, a P/E ratio of 16.71 and a beta of 1.81. The stock’s fifty day moving average is $2.80 and its two-hundred day moving average is $2.48.
Oramed Pharmaceuticals (NASDAQ:ORMP – Get Free Report) last issued its earnings results on Wednesday, March 6th. The biotechnology company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.04. Analysts expect that Oramed Pharmaceuticals Inc. will post -0.26 EPS for the current year.
Institutional Investors Weigh In On Oramed Pharmaceuticals
About Oramed Pharmaceuticals
Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.
Read More
- Five stocks we like better than Oramed Pharmaceuticals
- How to Effectively Use the MarketBeat Ratings Screener
- AMD is Down 35%. Now is the Time to Buy the Dip
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Amazon Stands Tall: New Highs Are in Sight
- Comparing and Trading High PE Ratio Stocks
- Chesapeake Energy Stock is The Energy Play, Earnings Confirm
Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.